Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric or GEJ Adenocarcinoma
NCT07464756Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, Rivoceranib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Started Apr 2026; status: recruiting.
02
Drugs
retlirafusp alfaRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07464756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464756.